Citations

Mayo Clinic

Showing 10 of 108599 citations.

Revisiting an Old Place: Single-Surgeon Experience on Post-Mastectomy Subcutaneous Implant-Based Breast Reconstruction
Woo, Alice , Harless, Christin A., Jacobson, Steven R., Harless, Christin

The Breast Journal | March 14, 2017 | Volume: 23 | Issue: 5 | Pages: 545-553

10.1111/tbj.12790 | PMID 28295975 Get It

Epidemiology of uterine fibroids: a systematic review
Cookson, CL, Gandolfo, RA, Schulze‐Rath, Renate , Stewart, Elizabeth A.

BJOG: An International Journal of Obstetrics & Gynaecology | March 14, 2017 | Volume: 124 | Issue: 10 | Pages: 1501-1512

10.1111/1471-0528.14640 | PMID 28296146 Get It

Background Uterine fibroids ( UF s) are the most common neoplasm affecting women that can cause significant morbidity and may adversely impact fertility. Objectives To examine UF epidemiology and to evaluate the relative strengths of putative risk factors. Search strategy MEDLINE and Embase were searched for studies published in English between January 1995 and April 2015. Selection criteria Publications reporting relevant data from registries and other observational studies with over 1000 patients and single‐centre studies with over 100 patients were selected. Data collection and analysis Data on UF incidence, prevalence and associated risk factors were extracted from 60 publications. Main results Wide ranges were reported in both UF incidence (217–3745 cases per 100 000 women‐years) and prevalence (4.5–68.6%), depending on study populations and diagnostic methods. Black race was the only factor that was recurrently reported to increase UF risk, by two–threefold compared with white race. Eleven other factors affected UF risk to a magnitude similar to or greater than race. Age, premenopausal state, hypertension, family history, time since last birth, and food additive and soybean milk consumption increased UF risk; use of oral contraceptives or the injectable contraceptive depot medroxyprogesterone acetate, smoking in women with low body mass index and parity reduced UF risk. Conclusions We identified 12 risk factors that play an important role in UF epidemiology. The UF risk factor with the strongest evidence is black race. High‐quality prospective observational data are needed to improve our understanding of UF epidemiology, and thus its aetiology and optimal management. Tweetable abstract Uterine fibroids occur in about 70% of women. Black race and 11 other factors affect uterine fibroid risk.
Assessing the colonic microbiome, hydrogenogenic and hydrogenotrophic genes, transit and breath methane in constipation
Wolf, Patricia G. , Parthasarathy, Gopanandan , Chen, J., O’Connor, Helen M. , Bharucha, Adil E. , Gaskins, H. Rex , Bharucha, A E , Chia, Nicholas

Neurogastroenterology & Motility | March 14, 2017 | Volume: 29 | Issue: 10 | Pages: 1-9

10.1111/nmo.13056 | PMID 28295896 Get It

AbstractBackgroundDifferences in the gut microbiota and breath methane production have been observed in chronic constipation, but the relationship between colonic microbiota, transit, and breath tests remains unclear.MethodsIn 25 healthy and 25 constipated females we evaluated the sigmoid colonic mucosal and fecal microbiota using 16S rRNA gene sequencing, abundance of hydrogenogenic FeFe (FeFe‐hydA) and hydrogenotrophic (methyl coenzyme M reductase A [mrcA] and dissimilatory sulfite reductase A [dsrA]) genes with real‐time qPCR assays, breath hydrogen and methane levels after oral lactulose, and colonic transit with scintigraphy.Key ResultsBreath hydrogen and methane were not correlated with constipation, slow colon transit, or with abundance of corresponding genes. After adjusting for colonic transit, the abundance of FeFehydA, dsrA, and mcrA were greater (P<.005) in colonic mucosa, but not stool, of constipated patients. The abundance of the selected functional gene targets also correlated with that of selected taxa. The colonic mucosal abundance of FeFe‐hydA, but not mcrA, correlated positively (P<.05) with breath methane production, slow colonic transit, and overall microbiome composition. In the colonic mucosa and feces, the abundance of hydrogenogenic and hydrogenotrophic genes were positively correlated (P<.05). Breath methane production was not associated with constipation or colonic transit.Conclusions & InferencesCorroborating our earlier findings with 16S rRNA genes, colonic mucosal but not fecal hydrogenogenic and hydrogenotrophic genes were more abundant in constipated vs. healthy subjects independent of colonic transit. Breath gases do not directly reflect the abundance of target genes contributing to their production.
Comparison of linear and nonlinear programming approaches for “worst case dose” and “minmax” robust optimization of intensity‐modulated proton therapy dose distributions
Zaghian, Maryam, Cao, Wenhua , Liu, Wei , Kardar, Laleh, Randeniya, S, Mohan, Radhe , Lim, Gino J. , Liu, Wei

Journal of Applied Clinical Medical Physics | March 14, 2017 | Volume: 18 | Issue: 2 | Pages: 15-25

10.1002/acm2.12033 | PMID 28300378 Get It

AbstractRobust optimization of intensity‐modulated proton therapy (IMPT) takes uncertainties into account during spot weight optimization and leads to dose distributions that are resilient to uncertainties. Previous studies demonstrated benefits of linear programming (LP) for IMPT in terms of delivery efficiency by considerably reducing the number of spots required for the same quality of plans. However, a reduction in the number of spots may lead to loss of robustness. The purpose of this study was to evaluate and compare the performance in terms of plan quality and robustness of two robust optimization approaches using LP and nonlinear programming (NLP) models. The so‐called “worst case dose” and “minmax” robust optimization approaches and conventional planning target volume (PTV)‐based optimization approach were applied to designing IMPT plans for five patients: two with prostate cancer, one with skull‐based cancer, and two with head and neck cancer. For each approach, both LP and NLP models were used. Thus, for each case, six sets of IMPT plans were generated and assessed: LP‐PTV‐based, NLP‐PTV‐based, LP‐worst case dose, NLP‐worst case dose, LP‐minmax, and NLP‐minmax. The four robust optimization methods behaved differently from patient to patient, and no method emerged as superior to the others in terms of nominal plan quality and robustness against uncertainties. The plans generated using LP‐based robust optimization were more robust regarding patient setup and range uncertainties than were those generated using NLP‐based robust optimization for the prostate cancer patients. However, the robustness of plans generated using NLP‐based methods was superior for the skull‐based and head and neck cancer patients. Overall, LP‐based methods were suitable for the less challenging cancer cases in which all uncertainty scenarios were able to satisfy tight dose constraints, while NLP performed better in more difficult cases in which most uncertainty scenarios were hard to meet tight dose limits. For robust optimization, the worst case dose approach was less sensitive to uncertainties than was the minmax approach for the prostate and skull‐based cancer patients, whereas the minmax approach was superior for the head and neck cancer patients. The robustness of the IMPT plans was remarkably better after robust optimization than after PTV‐based optimization, and the NLP‐PTV‐based optimization outperformed the LP‐PTV‐based optimization regarding robustness of clinical target volume coverage. In addition, plans generated using LP‐based methods had notably fewer scanning spots than did those generated using NLP‐based methods.
Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma
Leon‐Ferre, Roberto A. , Kottschade, Lisa A. , Block, Matthew S. , Dronca, Roxana , Creagan, Edward T. , Allred, Jacob B., Lowe, Val J. , McWilliams, Robert R. , Markovic, Svetomir N.

Melanoma Research | March 14, 2017 | Volume: 27 | Issue: 4 | Pages: 335-341

10.1097/cmr.0000000000000344 | PMID 28296712 Get It

The optimal surveillance for patients with resected high-risk melanoma is controversial. Select locoregional or oligometastatic recurrences can be cured with salvage resection. Data on the ability of PET/CT to detect such recurrences are sparse. We evaluated whether surveillance PET/CT in patients with resected stage III–IV melanoma led to detection of clinically occult recurrences amenable to curative-intent salvage treatment. We retrospectively identified 1429 melanoma patients who underwent PET/CT between January 2008 and October 2012 at Mayo Clinic (Rochester, Minnesota). A total of 1130 were excluded because of stage I–II, ocular or mucosal melanoma, incomplete resection, PET/CT not performed for surveillance or performed at a different institution, and records not available. A total of 299 patients were eligible. Overall, 162 (52%) patients developed recurrence [locoregional: 77 (48%), distant: 85 (52%)]. The first recurrence was clinically occult in 98 (60%) and clinically evident in 64 (40%). Clinically evident recurrences were more often superficial (skin, subcutaneous, or nodal) or in the brain, whereas clinically occult recurrences more often visceral. Overall, 90% of all recurrences were detected by 2.8 years. In all, 70% of patients with recurrence underwent curative-intent salvage treatment (locoregional: 94%, distant: 48%), with similar rates for clinically occult versus clinically evident recurrences (66 vs. 75%, P=0.240). Overall survival was superior among those who underwent curative-intent salvage treatment [5.9 vs. 1.2 years; hazard ratio=4.27, 95% confidence interval (CI)=2.68–6.80; P<0.001], despite 79% developing recurrence again. PET/CT had high sensitivity (88%, 95% CI=79.94–93.31%), specificity (90%, 95% CI=88.56–91.56%), and negative predictive value (99%, 95% CI=98.46–99.52%). However, the positive predictive value was only 37% (95% CI=31.32–43.68%). In patients with resected stage III–IV melanoma, surveillance PET/CT detected a large proportion of clinically occult recurrences amenable to curative-intent salvage treatment. Despite a high rate of second relapse, curative-intent salvage treatment was associated with superior overall survival. Even though PET/CT had high sensitivity, specificity, and negative predictive value, positive predictive value was poor, highlighting the need for histologic confirmation of PET/CT-detected abnormalities.
Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma – tissue remains the issue
Pham, Anthony , Jevremović, Dragan , Wiseman, Gregory A., Feldman, Andrew L. , Ristow, Kay M., Pham, Anthony Q, Broski, Stephen M. , Habermann, Thomas M. , Maurer, Matthew J. , Witzig, Thomas E. , Feldman, Andrew L , Jevremovic, Dragan

Leukemia & Lymphoma | March 14, 2017 | Volume: 58 | Issue: 10 | Pages: 2342-2348

10.1080/10428194.2017.1300891 | PMID 28290723 Get It

Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens
Loudig, Olivier , Ye, Kenny , Lin, Juan , Wang, Yihong , Ramnauth, Andrew, Stark, Azadeh , Chitale, Dhananjay , Greenlee, Robert T. , Multerer, Deborah, Honda, Stacey , Daida, Yihe G. , Glass, Andrew G., Rohan, Thomas E. , Ben‐Dov, Iddo Z. , Wang, Tao , Liu, Christina , Feigelson, Heather Spencer , Couch, Fergus J. , Wang, Yihong , Loudig, Olivier , Chitale, Dhananjay A

International Journal of Molecular Sciences | March 14, 2017 | Volume: 18 | Issue: 3 | Pages: 627

10.3390/ijms18030627 | PMID 28335433 Get It

Formalin-fixed paraffin-embedded (FFPE) specimens, when used in conjunction with patient clinical data history, represent an invaluable resource for molecular studies of cancer. Even though nucleic acids extracted from archived FFPE tissues are degraded, their molecular analysis has become possible. In this study, we optimized a laboratory-based next-generation sequencing barcoded cDNA library preparation protocol for analysis of small RNAs recovered from archived FFPE tissues. Using matched fresh and FFPE specimens, we evaluated the robustness and reproducibility of our optimized approach, as well as its applicability to archived clinical specimens stored for up to 35 years. We then evaluated this cDNA library preparation protocol by performing a miRNA expression analysis of archived breast ductal carcinoma in situ (DCIS) specimens, selected for their relation to the risk of subsequent breast cancer development and obtained from six different institutions. Our analyses identified six miRNAs (miR-29a, miR-221, miR-375, miR-184, miR-363, miR-455-5p) differentially expressed between DCIS lesions from women who subsequently developed an invasive breast cancer (cases) and women who did not develop invasive breast cancer within the same time interval (control). Our thorough evaluation and application of this laboratory-based miRNA sequencing analysis indicates that the preparation of small RNA cDNA libraries can reliably be performed on older, archived, clinically-classified specimens.
Comprehensive assessment of renal tumour complexity in a large percutaneous cryoablation cohort
Bhindi, Bimal , Thompson, R. Houston, Mason, Ross , Haddad, M , Geske, Jennifer R. , Hannon, James D. , Boorjian, Stephen A. , Leibovich, Bradley C. , Atwell, Thomas D. , Schmit, Grant D. , Thompson, Robert Houston, Mason, Ross J, Haddad, Mustafa M, Kurup, Anil Nicholas, Kurup, A. Nicholas , Geske, Jennifer

BJU International | March 14, 2017 | Volume: 119 | Issue: 6 | Pages: 905-912

10.1111/bju.13841 | PMID 28296030 Get It

Objective To evaluate the association between renal tumour complexity and outcomes in a large cohort of patients undergoing percutaneous cryoablation ( PCA ). Patients and Methods Patients with renal tumours treated with PCA were identified using our prospectively maintained ablation registry (2003–2015). Salvage procedures and inherited tumour syndromes were excluded. The associations between R.E.N.A.L. nephrometry score ( NS ) and risk of complications, renal function impairment, local failure and cancer‐specific mortality ( CSM ) were evaluated using univariate and multivariable logistic, linear and Cox regression models. Results The cohort included 618 tumours treated during 580 procedures in 565 patients. The median (interquartile range [ IQR ]) follow‐up was 34 (14.66) months. Complications (any grade) during a procedure ( n [total] = 87, 15%) were more frequent with higher NS ( NS 4–6: 10%; NS 7–9: 14%; NS 10–12: 36%; P < 0.001). Higher NS was independently associated with risk of complications (odds ratio [ OR ; per 1 point] = 1.3; 95% confidence interval [ CI ] 1.2–1.5; P < 0.001). Of all the NS components, tumour size was the most strongly associated with complication risk ( OR 3.4; 95% CI 2.2–5.2; P < 0.001). The median ( IQR ) decline in glomerular filtration rate ( GFR ) from baseline was 9% (0, 22) at last follow‐up. Each additional point in NS was associated with a 1.3% (95% CI 0.4–2.1; P = 0.005) greater GFR decline from baseline. NS was not significantly associated with local failure ( n [total] = 14, 2%; NS 4–6: 2%; NS 7–9: 3%; NS 10–12: 5%; P = 0.32) or CSM ( n [total] = 8, 2%; NS 4–6: 2%; NS 7–9: 3%; NS 10–12: 2%; P = 0.88). Conclusion In high‐complexity tumours PCA was associated with a tumour size‐driven increased risk of post‐procedural complications. Higher NS was associated with a small, clinically minor additional decline in renal function. Risks for local failure and CSM were low, regardless of tumour complexity.
Mild Cognitive Impairment and Exposure to General Anesthesia for Surgeries and Procedures: A Population-Based Case–Control Study
Roberts, Rosebud O., Price, Lauren L., Schulz, Hunter P., Tatsuyama, Christie L., Schroeder, Darrell R. , Hanson, Andrew C. , Petersen, Ronald C. , Šprung, Juraj , Knopman, David S. , Weingarten, Toby N. , Warner, David O. , Schroeder, Darrell

Anesthesia & Analgesia | March 14, 2017 | Volume: 124 | Issue: 4 | Pages: 1277-1290

10.1213/ane.0000000000001725 | PMID 28291057 Get It

BACKGROUND: To examine whether exposure to general anesthesia for procedures at age ≥40 years is associated with prevalent mild cognitive impairment (MCI) in the elderly. METHODS: A case–control study nested within a population-based cohort. Olmsted County, Minnesota, residents, aged 70–91 years, underwent baseline evaluations that included the Clinical Dementia Rating scale, a neurologic evaluation, and neuropsychologic testing. Individuals identified with MCI (cases) at enrollment were matched 1:2 on age, sex, education, and apolipoprotein genotype with participants who were cognitively normal at the time of the index visit. Medical records from age 40 years until the index visit were reviewed to determine exposures to general anesthesia. Conditional logistic regression, taking into account the matched set study design and adjusting for MCI risk factors, was used to assess whether exposure to anesthesia after the age of 40 years was associated with prevalent MCI. RESULTS: A total of 387 Mayo Clinic Study of Aging participants (219 males, 168 females) were diagnosed with MCI at enrollment with mean age of 81 ± 5 years. Exposure to general anesthesia after the age of 40 years was not significantly associated with prevalent MCI when analyzed as a dichotomous variable (any versus none, adjusted odds ratio, 0.97 [95% confidence interval, 0.68–1.40]) or the number of exposures (odds ratio, 1.13 [0.74–1.72], 0.81 [0.53–1.22], and 1.03 [0.67–1.58] for 1, 2–3, and ≥4 exposures, respectively, with no exposure as the reference). Similar results were obtained for exposure to anesthesia after the age of 60 years and during 5, 10, and 20 years before the first visit. CONCLUSIONS: Exposure to general anesthesia for procedures at age ≥40 years was not associated with prevalent MCI in the elderly.
Alzheimer's disease: The next frontier—Special Report 2017
Karlawish, Jason , Rocca, Walter A. , Snyder, Heather M. , Jack, Clifford R. , Carrillo, María C.

Alzheimer's & Dementia | March 14, 2017 | Volume: 13 | Issue: 4 | Pages: 374-380

10.1016/j.jalz.2017.02.006 | PMID 28314660 Get It

In the history of medicine, one means to progress is when we make the decision that our assumptions and definitions of disease are no longer consistent with the scientific evidence, and no longer serve our health care needs. The arc of scientific progress is now requiring a change in how we diagnose Alzheimer's disease. Both the National Institute on Aging—Alzheimer's Association (NIA‐AA) 2011 workgroup and the International Work Group (IWG) have proposed guidelines that use detectable measures of biological changes in the brain, commonly known as biological markers, or biomarkers, as part of the diagnosis. This Special Report examines how the development and validation of Alzheimer's disease biomarkers—including those detectable in the blood or cerebral spinal fluid, or through neuroimaging—is a top research priority. This has the potential to markedly change how we diagnose Alzheimer's disease and, as a result, how we count the number of people with this disease. As research advances a biomarker‐based method for diagnosis and treatment at the earliest stages of Alzheimer's disease, we envision a future in which Alzheimer's disease is placed in the same category as other chronic diseases, such as cardiovascular disease or diabetes, which can be readily identified with biomarkers and treated before irrevocable disability occurs.